[1]周谷城,张志明,刘永琦,等.清肺通络方治疗新型冠状病毒肺炎32例临床疗效分析[J].西部中医药,2021,34(12):4-8.[doi:10.12174/j.issn.2096-9600.2021.12.02]
　ZHOU Gucheng,ZHANG Zhiming,LIU Yongqi,et al.Clinical Effects of Lung-clearing Collateral-dredging Prescription in Treating 32 Cases of COVID-19[J].Western Journal of Traditional Chinese Medicine,2021,34(12):4-8.[doi:10.12174/j.issn.2096-9600.2021.12.02]
点击复制

清肺通络方治疗新型冠状病毒肺炎32例临床疗效分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年12期
页码:
4-8
栏目:
出版日期:
2021-12-15

文章信息/Info

Title:
Clinical Effects of Lung-clearing Collateral-dredging Prescription in Treating 32 Cases of COVID-19
作者:
周谷城1, 张志明2, 刘永琦1,3, 周婷1, 柯宜诚1, 史桐凡1, 牛帆1, 李娟2, 张利英1,3
1.甘肃中医药大学/甘肃省高校重大疾病分子医学与中医药防治研究重点实验室，甘肃 兰州 730000
2.甘肃中医药大学附属医院/甘肃省中西医结合防治肿瘤临床中心
3.甘肃中医药大学/敦煌医学与转化省部共建教育部重点实验室
Author(s):
ZHOU Gucheng1, ZHANG Zhiming2, LIU Yongqi1,3, ZHOU Ting1, KE Yicheng1, SHI Tongfan1, NIU Fan1, LI Juan2, ZHANG Liying1,3
1.Gansu University of Chinese Medicine/Gansu Provincial Key Laboratory for Molecular Medicine and TCM Prevention and Treatment for Major Diseases in Colleges and University, Lanzhou 73000, China
2.Affiliated Hospital of Gansu University of Chinese Medicine/Gansu Provincial Clinical Center for Prevention and Treatment of Tumor with Integrated Traditional Chinese and Western Medicine
3.Gansu University of Chinese Medicine/Key Laboratory for Transfer of Dunhuang Medicine at the Provincial and Ministerial Level
关键词:
新型冠状病毒肺炎; 清肺通络方; 临床疗效分析
Keywords:
COVID-19; lung-clearing collateral-dredging prescription; the analysis of clinical effects
分类号:
R563.1
DOI:
10.12174/j.issn.2096-9600.2021.12.02
文献标志码:
A
摘要:
目的探讨清肺通络方对新型冠状病毒肺炎的治疗效果。 方法从甘肃地区91例新型冠状病毒肺炎患者中筛选出中西医结合治疗中符合使用清肺通络方的患者32例，收集患者临床症状资料、外周血白细胞、淋巴细胞、肝酶、肌酶、C反应蛋白、肺部CT、中医证型等指标，比较患者用药前后上述各指标变化。 结果32例患者中，男16例，女16例，平均年龄41岁。普通型患者19例，重型患者13例。中医证型以湿热郁肺（65.63%）、和湿温壅肺（34.38%）为主。患者治疗前的主要症状为发热（40.63%）、乏力（28.13%）、咽痛（9.38%）、咳嗽（90.63%）、咳痰（56.25%）、头晕头痛（6.25%）、胸闷气短（40.63%）、腹泻（3.13%）、食欲不振（21.88%）。使用清肺通络方后，患者咳嗽、咳痰的症状缓解率是89.66%和88.89%，其余缓解率为100%。患者治疗前主要以白细胞总数降低（46.88%）、淋巴细胞百分比降低（56.25%）、中性粒细胞百分比升高（43.75%）、淋巴细胞绝对值降低（56.25%）、C反应蛋白升高（40.63%）、血沉升高（53.13%）、乳酸脱氢酶升高（34.38%）和总胆红素升高（34.38%）为主。治疗后，咽拭子病毒核酸检测三次阴性，肺部CT示感染病灶已吸收，出院患者咳嗽、咳痰症状消失，血常规、血生化中上述异常关键指标均基本恢复正常，符合出院标准，治愈率100%，且未发生核酸检测转阳者复发病例。 结论清肺通络方可有效治疗处于疾病中期的新型冠状病毒肺炎患者。
Abstract:
ObjectiveTo discuss therapeutic effects of lung-clearing collateral-dredging prescription in the treatment of COVID-19. MethodsAll 32 patients who met the standard of using lung-clearing collateral-dredging prescription were screened from 91 COVID-19 patients in Gansu region, to collect TCM patterns, lung CT, CRP, muscle enzymes, liver enzymes, lymphocytes and leukocytes in peripheral blood and clinical symptoms of the patients, to compare the changes of these indexes before and after the medications. ResultsAmong 32 patients, there were 16 cases of male patients, and 16 cases of female patients, average age was 41 years, they contained 19 common patients and 13 severe ones. TCM patterns were damp-heat stagnating in lung (65.63%) and damp-warm obstructing lung (34.38%) mainly. The main symptoms of the patients before treating were fever (40.63%), weakness (28.13%), sore throat (9.38%), cough (90.63%), expectoration (56.25%), dizziness and headache (6.25%), chest tightness and panting (40.63%), diarrhea (3.13%) and poor appetite (21.88%). After applying lung-clearing collateral-dredging prescription, cough and expectoration remission rates of the patients were 89.66% and 88.89%, the remission rate of other symptoms was 100%. Before treating, the patients manifested total number of leukocytes decreased (46.88%), decreased percentage of lymphocytes (56.25%), increased percentage of neutrophils (43.75%), the absolute value of lymphocytes decreased (56.25%), elevated CRP (40.63%), increased ESR (53.13%), lactate dehydrogenase (34.38%) and total bilirubin (34.38%) mostly. After treating, the nucleic acid test of pharyngeal swab was negative three times, pulmonary CT indicated that the infected lesion has been absorbed, cough and expectoration of the discharged patients disappeared, the abnormal indexes of routine blood test and blood chemical test returned to normal basically, which met the discharge standards, cure rate reached 100%, and no recurrent cases was found. ConclusionLung-clearing collateral-dredging prescription could effectively treat COVID-19 patients in the middle of the disease.

相似文献/References:

[1]李赟,王彩弟,王建云,等.简约远程中医诊疗在新型冠状病毒肺炎隔离病区中的应用[J].西部中医药,2020,33(S1):1.
　LI Yun,WANG Caidi,WANG Jianyun,et al.The Application of Simple Remote TCM Diagnosis and Treatment to COVID-19 Quarantined Inpatient Area[J].Western Journal of Traditional Chinese Medicine,2020,33(12):1.
[2]宋忠阳,雍文兴,张利英,等.新型冠状病毒肺炎的中医临床特征与辨证论治——甘肃经验*[J].西部中医药,2020,33(S1):3.
　SONG Zhongyang,YONG Wenxing,ZHANG Liying,et al.The Experience of TCM Clinical Characteristics, Syndrome Differentiation and Treatment for COVID-19 in Gansu Province[J].Western Journal of Traditional Chinese Medicine,2020,33(12):3.
[3]杜洪霖,马战平△.西北地区新型冠状病毒肺炎的中医特点及防治*[J].西部中医药,2020,33(S1):5.
　DU Honglin,MA Zhanping.TCM Characteristics, the Prevention and Treatment of COVID-19 in Northwest China[J].Western Journal of Traditional Chinese Medicine,2020,33(12):5.
[4]潘文,李盛华,王晓萍,等.中医对新型冠状病毒肺炎的认识与防治探讨[J].西部中医药,2020,33(S1):7.
　PAN Wen,LI Shenghua,WANG Xiaoping,et al.On TCM Understanding, the Prevention and Treatment of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(12):7.
[5]杨海侠,张银萍△,杨长虹,等.新型冠状病毒肺炎疑似患者留观隔离期的护理体会[J].西部中医药,2020,33(S1):13.
[6]丁潇,邹忆怀△,辛大永,等.北京顺义地区新型冠状病毒肺炎的中医临床证候与CT表现[J].西部中医药,2020,33(S1):16.
　DING Xiao,ZOU Yihuai,XIN Dayong,et al.TCM Clinical Syndromes and CT Manifestations of COVID-19 in Shunyi District of Beijing[J].Western Journal of Traditional Chinese Medicine,2020,33(12):16.
[7]桑天庆,周红光△.中医药在新型冠状病毒肺炎疫情中的应用[J].西部中医药,2020,33(S1):18.
　SANG Tianqing,ZHOU Hongguang.TCM Applied to Epidemic Situation of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(12):18.
[8]闫向勇,李 俊,燕忠生△.武汉地区新型冠状病毒肺炎中医证候及病机特点[J].西部中医药,2020,33(S1):20.
　YAN Xiangyong,LI Jun,YAN Zhongsheng.On the Characteristics of TCM Patterns and the Pathogenesis of COVID-19 in Wuhan Region[J].Western Journal of Traditional Chinese Medicine,2020,33(12):20.
[9]曾建峰,李乐愚,缪灿铭,等.岭南道地药材在中山地区新型冠状病毒肺炎防治中的应用*[J].西部中医药,2020,33(S1):24.[doi:10.1056/NEJMoa-2001017]
　and Treatment of COVID-9 in Zhongshan Region.The Application of Lingnan Genuine Drugs to the Prevention[J].Western Journal of Traditional Chinese Medicine,2020,33(12):24.[doi:10.1056/NEJMoa-2001017]
[10]朱玉,黎玉婷,姚德蛟△.从中西医不同角度分析麻杏石甘汤治疗新型冠状病毒肺炎的作用[J].西部中医药,2020,33(S1):26.
　of Traditional Chinese Medicine and Western Medicine.The Functions of Maxing Shigan Tang in the Treatment for COVID-19 from the Angles[J].Western Journal of Traditional Chinese Medicine,2020,33(12):26.

备注/Memo

备注/Memo:
周谷城（1995—），男，在读硕士研究生。研究方向：肿瘤疾病的中西医结合防治。甘肃省新型冠状病毒肺炎（NCP）科技重大专项（2020年）；甘肃省高校重大疾病分子医学与中医药防治研究重点实验室NCP防治科研专项开放基金（FZYX20-2，FZYX20-8）；兰州市城关区新型冠状病毒肺炎科技专项（2020JSCX0025）。
更新日期/Last Update: 2021-12-15